260 related articles for article (PubMed ID: 24129710)
1. (11)C-acetate as a new biomarker for PET/CT in patients with multiple myeloma: initial staging and postinduction response assessment.
Lin C; Ho CL; Ng SH; Wang PN; Huang Y; Lin YC; Tang TC; Tsai SF; Rahmouni A; Yen TC
Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):41-9. PubMed ID: 24129710
[TBL] [Abstract][Full Text] [Related]
2. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
[TBL] [Abstract][Full Text] [Related]
3. PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics.
Sachpekidis C; Goldschmidt H; Hose D; Pan L; Cheng C; Kopka K; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1343-53. PubMed ID: 24562650
[TBL] [Abstract][Full Text] [Related]
4. The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma.
Sager S; Ergül N; Ciftci H; Cetin G; Güner SI; Cermik TF
Skeletal Radiol; 2011 Jul; 40(7):843-7. PubMed ID: 21229354
[TBL] [Abstract][Full Text] [Related]
5. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
Dammacco F; Rubini G; Ferrari C; Vacca A; Racanelli V
Clin Exp Med; 2015 Feb; 15(1):1-18. PubMed ID: 25218739
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
Mesguich C; Hulin C; Latrabe V; Lascaux A; Bordenave L; Hindié E; Marit G
Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
[TBL] [Abstract][Full Text] [Related]
8. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
Ak I; Gulbas Z
Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
[TBL] [Abstract][Full Text] [Related]
9. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.
Fonti R; Larobina M; Del Vecchio S; De Luca S; Fabbricini R; Catalano L; Pane F; Salvatore M; Pace L
J Nucl Med; 2012 Dec; 53(12):1829-35. PubMed ID: 23071351
[TBL] [Abstract][Full Text] [Related]
10. 11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma.
Chen M; Zhu W; Du J; Yang C; Han B; Zhou D; Huo L; Zhuang J
Sci Rep; 2021 Nov; 11(1):22188. PubMed ID: 34773054
[TBL] [Abstract][Full Text] [Related]
11. Imaging CXCR4 receptors expression for staging multiple myeloma by using
Shekhawat AS; Singh B; Malhotra P; Watts A; Basher R; Kaur H; Hooda M; Radotra BD
Br J Radiol; 2022 Aug; 95(1136):20211272. PubMed ID: 35731811
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study.
Fonti R; Pace L; Cerchione C; Catalano L; Salvatore B; De Luca S; Pane F; Salvatore M; Del Vecchio S
Clin Nucl Med; 2015 Apr; 40(4):303-8. PubMed ID: 25608167
[TBL] [Abstract][Full Text] [Related]
13. Comparison of (11)C-4'-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma.
Okasaki M; Kubota K; Minamimoto R; Miyata Y; Morooka M; Ito K; Ishiwata K; Toyohara J; Inoue T; Hirai R; Hagiwara S; Miwa A
Ann Nucl Med; 2015 Apr; 29(3):224-32. PubMed ID: 25421383
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
[TBL] [Abstract][Full Text] [Related]
15. 11C-acetate PET/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET/CT.
Ho CL; Chen S; Leung YL; Cheng T; Wong KN; Cheung SK; Liang R; Chim CS
J Nucl Med; 2014 May; 55(5):749-52. PubMed ID: 24676754
[TBL] [Abstract][Full Text] [Related]
16. Hybrid simultaneous whole-body 2-[
Jamet B; Carlier T; Bailly C; Bodet-Milin C; Monnet A; Frampas E; Touzeau C; Moreau P; Kraeber-Bodere F
Eur Radiol; 2023 Sep; 33(9):6438-6447. PubMed ID: 37022439
[TBL] [Abstract][Full Text] [Related]
17. Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome.
Tirumani SH; Sakellis C; Jacene H; Shinagare AB; Munshi NC; Ramaiya NH; Van den Abbeele AD
Clin Nucl Med; 2016 Jan; 41(1):e7-13. PubMed ID: 26252323
[TBL] [Abstract][Full Text] [Related]
18. Dual-tracer PET/CT scan after injection of combined [
Withofs N; Beguin Y; Cousin F; Tancredi T; Simoni P; Alvarez-Miezentseva V; De Prijck B; Hafraoui K; Bonnet C; Baron F; Hustinx R; Caers J
Hematol Oncol; 2019 Apr; 37(2):193-201. PubMed ID: 30821017
[TBL] [Abstract][Full Text] [Related]
19. Comparison of [
Stokke C; Nørgaard JN; Feiring Phillips H; Sherwani A; Nuruddin S; Connelly J; Schjesvold F; Revheim ME
Mol Imaging Biol; 2022 Oct; 24(5):842-851. PubMed ID: 35501622
[TBL] [Abstract][Full Text] [Related]
20. 11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement.
Lapa C; Knop S; Schreder M; Rudelius M; Knott M; Jörg G; Samnick S; Herrmann K; Buck AK; Einsele H; Lückerath K
Theranostics; 2016; 6(2):254-61. PubMed ID: 26877783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]